Siemens Healthineers Collaboration

RNS Number : 2022Q

Oncimmune Holdings PLC

17 February 2023

 

17 February 2023

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Siemens Healthineers and Oncimmune partner to improve malignancy risk assessment of indeterminate pulmonary nodules

Collaboration will access data from the ECLS trial, the large randomised study into the utility of EarlyCDT Lung in asymptomatic screening

Oncimmune Holdings plc (AIM: ONC.L), the leading global immunodiagnostics group, announces a collaboration with Siemens Healthineers aimed at improving malignancy risk assessment of Indeterminate Pulmonary Nodules ("IPNs").

Lung cancer has the highest mortality rate and one of the worst five-year survival rates of all cancers¹. What makes lung cancer so deadly is that the symptoms are non-specific and patients often only seek medical attention when tumors have exceeded a critical size, or when cancer cells have attacked the lymph nodes or have metastasized. The best chance of survival is to diagnose lung cancer as early as possible. Early detection and the introduction of screening programs have the potential to substantially improve lung cancer healthcare and clinical outcomes.  

The collaboration brings together Oncimmune's EarlyCDT Lung blood test with Siemens Healthineers' AI-Rad Companion Chest CT (computerised tomography), an AI-powered radiology assistant that supports radiologists by performing automatic post-processing, quantifying and interpreting data. By combining autoantibody biomarker data with imaging results, it is anticipated that malignancy risk assessment of IPNs can be improved.

The collaboration will access data from the Early Detection of Cancer of the Lung Scotland (ECLS) trial, the large randomised study into the utility of EarlyCDT Lung in asymptomatic screening.

Dr Adam M Hill, CEO of Oncimmune said: "If lung cancer is detected early when it doesn't yet cause symptoms, the chances for curative treatment to work are good: the average five-year survival rate for the earliest stage of the disease can be as high as 90%. Oncimmune's easy-to-use EarlyCDT Lung blood test has proven utility in successfully triaging patients with cancerous nodules into early intervention. It is our hope that combining this test with Siemens Healthineers' AI-Rad Companion Chest CT will improve diagnostic accuracy in those patients with more difficult to diagnose lung cancer."

Sebastian Schmidt, MD, Head of Medical Affairs, Innovation and Strategy at Siemens Healthineers Computed Tomography said: "Lung cancer screening is proven to work and reduce mortality of this devastating disease. We believe that additionally, further improvement in outcomes and efficiency gains will be possible by combining imaging with lab markers - our collaboration with Oncimmune is an important first step in this direction."

For further information:

Oncimmune Holdings plc

Dr Adam M Hill, Chief Executive Officer

Matthew Hall, Chief Financial Officer

[e-mail]

Singer Capital Markets (Nominated Adviser and Broker)

Aubrey Powell, Harry Gooden, George Tzimas, James Fischer

[phone]

About Oncimmune

ImmunoINSIGHTS Service Business

Oncimmune is a leading immunodiagnostics developer, primarily focused on the growing fields of immuno-oncology, autoimmune disease and infectious diseases. The ImmunoINSIGHTS service business leverages Oncimmune's technology platform and methodologies across multiple diseases, to offer life-science organizations actionable insights for therapies across the development and product lifecycle. Our core immune-profiling technology is underpinned by our library of over eight thousand immunogenic proteins, one of the largest of its kind. This helps identify trial participants and patients into clinically relevant subgroups, enabling development of targeted and more effective treatments.

Oncimmune's ImmunoINSIGHTS service business is based at the Company's discovery research centre in Dortmund, Germany. The business platform enables life science organizations to optimize drug development and delivery, leading to more effectively targeted and safer treatments for patients.

The ImmunoINSIGHTS development team is based in the US and Europe and Oncimmune is seeking to replicate the Dortmund facility in the US in the medium term.

EarlyCDT Product Business

Oncimmune's immunodiagnostic technology, EarlyCDT®, can detect and help identify cancer on average four years earlier than standard clinical diagnosis. Our lead diagnostic test, EarlyCDT® Lung, targets a vast market estimated to grow to £3.8bn by 2024. With over 200,000 tests already performed for patients worldwide and its use being supported by peer reviewed data in over 12,000 patients, we are poised to become an integral component of future lung cancer detection programs, globally.

Oncimmune's diagnostic products business is located at its laboratory facility in Nottingham, UK. 

For more information, visit  www.oncimmune.com

About our partner, Siemens Healthineers

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) pioneers breakthroughs in healthcare. For everyone. Everywhere. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers and its regional companies are continuously developing their product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company's foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics, and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers' ability to provide high-quality, efficient care. In fiscal 2022, which ended on September 30, 2022, Siemens Healthineers, which has approximately 69,500 employees worldwide, generated revenue of around €21.7 billion and adjusted EBIT of almost €3.7 billion. Further information is available at www.siemens-healthineers.com

 

END

 

 

MSCSFUFMMEDSEFE